Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Lancet Oncol. 2018 Nov 30;20(1):88–99. doi: 10.1016/S1470-2045(18)30621-1

Table 4:

7-yr disease-free survival (DFS), cumulative incidence of breast cancer-free interval (BCFI), and distant recurrence according to select patient characteristics and treatment: NSABP B-42

Endpoint 7-Yr DFS (%) 7-Yr Cum. Incidence BCFI Event (%) 7-Yr Cum. Incidence Distant Recurrence (%)

Characteristic Placebo Letrozole Placebo Letrozole Placebo Letrozole
Pathologic Nodal Status Negative 83.4 (80.9, 85.7) 86.5 (84.2,88.5) 8.2 (6.5, 10.0) 5.3 (4.0, 6.8) 3.6 (2.5, 4.9) 2.2 (1.4, 3.2)
Positive 78.4 (75.2, 81.3) 82.4 (79.4, 85.0) 12.4 (10.1, 15.0) 8.7 (6.8, 10.8) 8.7 (6.8, 10.9) 6.3 (4.7, 8.2)
Prior Tamoxifen No 79.8 (77.1, 82.1) 82.0 (79.4, 84.3) 9.9 (8.2, 11.8) 6.8 (5.4, 8.5) 5.9 (4.5, 7.4) 3.6 (2.6, 4.9)
Yes 83.7 (80.6, 86.3) 88.8 (86.2, 91.0) 10.0 (7.8, 12.5) 6.5 (4.8, 8.5) 5.6 (4.0, 7.6) 4.4 (3.1, 6.1)
Lowest BMD T score ≤−2.0 77.9 (73.4, 81.7) 84.3 (80.2, 87.6) 9.3 (6.9, 12.3) 5.7 (3.6, 8.5) 7.3 (5.1, 9.9) 2.7 (1.5, 4.6)
>−2.0 82.4 (80.1, 84.4) 84.9 (82.8, 86.7) 10.2 (8.5, 11.9) 7.1 (5.8, 8.5) 5.3 (4.1, 6.6) 4.3 (3.3, 5.5)
Age, years < 60 86.0 (82.9, 88.6) 88.1 (85.2, 90.5) 9.5 (7.3, 12.1) 6.7 (4.9, 8.9) 5.9 (4.2, 8.0) 4.3 (2.9, 6.2)
≥60 78.8 (76.3, 81.2) 83.0 (80.6, 85.1) 10.2 (8.5, 12.1) 6.7 (5.4, 8.3) 5.7 (4.4, 7.2) 3.7 (2.8, 4.9)
Surgery Type Lumpectomy 83.4 (80.9, 85.6) 85.7 (83.3, 87.7) 8.7 (7.0, 10.5) 6.2 (4.8, 7.9) 3.1 (2.2, 4.3) 2.5 (1.7, 3.5)
Mastectomy 78.0 (74.6, 81.0) 83.3 (80.3, 85.9) 12.0 (9.6, 14.6) 7.5 (5.7, 9.5) 10.0 (7.8, 12.4) 6.1 (4.5, 8.1)